Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines
Hasumati Rahalkar, Hacer Coskun Cetintas, Mir-Saeed Shayegan Salek
Research output: Contribution to journal › Review article › peer-review
142Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Quality, Non-clinical and Clinical Considerations for Biosimilar Monoclonal Antibody Development: EU, WHO, USA, Canada, and BRICS-TM Regulatory Guidelines'. Together they form a unique fingerprint.